Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,250,719 papers from all fields of science
Search
Sign In
Create Free Account
SK&F 102922
Known as:
SK&F-102922
, SKF 102922
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
Metabolism of the leukotriene receptor antagonist 5-(2-(8-phenyloctyl)phenyl)-4,6-dithianonanedioic acid (SK&F 102922) in the guinea pig. Rearrangement of the acyl glucuronide.
J. Newton
,
K. Straub
,
+4 authors
R. Lynn
Drug Metabolism And Disposition
1992
Corpus ID: 23536583
A primary route of inactivation of leukotrienes and their receptor antagonists (LTRA) is metabolism by omega oxidation. SK&F…
Expand
1991
1991
Direct vasoconstriction evoked by A1-adenosine receptor stimulation in the cutaneous microcirculation.
K. Proctor
,
I. Stojanov
Circulation Research
1991
Corpus ID: 2476932
To determine whether the vasoconstriction evoked by A1-adenosine receptor stimulation in the skin circulation caused the release…
Expand
1990
1990
Leukotriene D4 excitation of rabbit distal colon arises in the region of the muscularis mucosae.
W. H. Percy
,
S. Y. Lee
,
M. Burton
,
T. Tolentino
,
R. Burakoff
American Journal of Physiology
1990
Corpus ID: 21593811
We previously have demonstrated in vivo that intra-arterial administration of leukotriene D4 (LTD4) causes increased myoelectric…
Expand
1989
1989
Arteriolar oxygen reactivity is inhibited by leukotriene antagonists.
W. Jackson
American Journal of Physiology
1989
Corpus ID: 2528521
Experiments were performed to test the hypothesis that the arteriolar constriction produced by elevated oxygen tensions in the…
Expand
1988
1988
Identification and transmembrane signaling of leukotriene D4 receptors in human mesangial cells.
M. Simonson
,
P. Menè
,
G. Dubyak
,
M. Dunn
American Journal of Physiology
1988
Corpus ID: 23344738
Although peptidoleukotriene (LTC4, LTD4) receptors have been characterized by radioligand binding studies, pathways of…
Expand
1988
1988
Characterization of the conjunctival vasopermeability response to leukotrienes and their involvement in immediate hypersensitivity.
R. Gary
,
D. Woodward
,
A. Nieves
,
L. S. Williams
,
J. Gleason
,
M. Wasserman
Investigative Ophthalmology and Visual Science
1988
Corpus ID: 26671749
The microvascular permeability response of the guinea pig conjunctiva to sulfidopeptide leukotrienes (LTs) was quantified as…
Expand
1987
1987
Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: mechanism of signal transduction for leukotriene-D4 receptors.
S. Mong
,
K. Hoffman
,
H. Wu
,
S. Crooke
Molecular Pharmacology
1987
Corpus ID: 38318351
Addition of leukotriene D4 (LTD4) to [3H]myo-inositol-labeled guinea pig lung induced rapid breakdown of inositol lipids…
Expand
1987
1987
Enhancement of leukotriene D4-induced contraction of guinea-pig isolated trachea by platelet activating factor.
P. E. Malo
,
M. Wasserman
,
D. Pfeiffer
Prostaglandins
1987
Corpus ID: 41527885
1987
1987
Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dog.
G. Kopia
,
R. Valocik
,
+4 authors
M. Wasserman
Journal of Pharmacology and Experimental…
1987
Corpus ID: 37073865
Anesthetized open-chest dogs were instrumented for the measurement of left circumflex coronary artery (LCX) blood flow and aortic…
Expand
1986
1986
Leukotriene D4 receptor-mediated synthesis and release of arachidonic acid metabolites in guinea pig lung: induction of thromboxane and prostacyclin biosynthesis by leukotriene D4.
S. Mong
,
H. Wu
,
M. A. Clark
,
J. Gleason
,
S. Crooke
Journal of Pharmacology and Experimental…
1986
Corpus ID: 30511211
The effects of the peptidoleukotrienes C4 (LTC4), D4 (LTD4), E4 (LTE4) and a series agonists and antagonists on arachidonic acid…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE